Compare SPIR & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPIR | MGTX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.5M | 881.7M |
| IPO Year | 2020 | 2018 |
| Metric | SPIR | MGTX |
|---|---|---|
| Price | $9.21 | $9.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $18.63 | ★ $27.75 |
| AVG Volume (30 Days) | 455.1K | ★ 588.9K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.98 | 33.02 |
| EPS | N/A | ★ 0.68 |
| Revenue | ★ $110,451,000.00 | $81,391,000.00 |
| Revenue This Year | $6.83 | $309.55 |
| Revenue Next Year | $30.81 | N/A |
| P/E Ratio | ★ N/A | $13.62 |
| Revenue Growth | 13.15 | ★ 144.57 |
| 52 Week Low | $6.60 | $6.62 |
| 52 Week High | $25.93 | $15.35 |
| Indicator | SPIR | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 43.56 |
| Support Level | $8.49 | $8.80 |
| Resistance Level | $9.94 | $10.08 |
| Average True Range (ATR) | 0.65 | 0.53 |
| MACD | 0.17 | 0.08 |
| Stochastic Oscillator | 69.10 | 49.03 |
Spire Global Inc provides space-based data, analytics, and space services, offering datasets and insights about Earth to support decision-making. It builds, owns, and operates a constellation of nanosatellites that observe the Earth in real time using radio frequency (RF) technology. Additionally, it offers Space Services solutions that allow customers to deploy and scale their own satellite constellations using its platform, ground station network, manufacturing facilities, and launch partnerships. The company derives revenue from providing data, insights and access to its cloud-based technology platform sold on a subscription basis.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.